Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis - PubMed
a day ago
- #hormone-therapy
- #breast-cancer
- #meta-analysis
- Menopausal hormone therapy (MHT) is widely used to alleviate menopausal symptoms.
- This meta-analysis evaluates the association between MHT and breast cancer risk across various regimens.
- Thirty-four studies were included, showing a significant but heterogeneous overall association (OR = 1.15, 95% CI: 1.09-1.22; I² = 92.4%).
- Subgroup analysis identified hormone type, use status, and region as key determinants of risk.
- Estrogen-progestin therapy (EPT) showed increased breast cancer risk (OR = 1.44, 95% CI: 1.26-1.64), while estrogen-only therapy (ET) showed no overall association (OR = 1.00, 95% CI: 0.91-1.10).
- Randomized controlled trials for ET suggested a protective effect (OR = 0.78, 95% CI: 0.70-0.87), differing from observational studies.
- The association between MHT and breast cancer risk exhibits marked geographical heterogeneity.
- The increased breast cancer risk is mainly attributable to EPT, particularly in current users in Europe.